• No results found

Human T Lymphocytes Are Permissive for Dengue Virus Replication

N/A
N/A
Protected

Academic year: 2019

Share "Human T Lymphocytes Are Permissive for Dengue Virus Replication"

Copied!
19
0
0

Loading.... (view fulltext now)

Full text

(1)

Human T Lymphocytes Are Permissive for Dengue Virus

Replication

Guilherme F. Silveira,

a

Pryscilla F. Wowk,

a

Allan H. D. Cataneo,

a

Paula F. dos Santos,

b

Murilo Delgobo,

b

Marco A. Stimamiglio,

c

Maria Lo Sarzi,

d

Ana Paula F. S. Thomazelli,

e

Ivete Conchon-Costa,

e

Wander R. Pavanelli,

e

Lis R. V. Antonelli,

f

André Báfica,

b

Daniel S. Mansur,

b

Claudia N. Duarte dos Santos,

a

Juliano Bordignon

a

aLaboratório de Virologia Molecular, Instituto Carlos Chagas, ICC/Fiocruz-PR, Curitiba, Paraná, Brazil

bLaboratório de Imunobiologia, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil

cLaboratório de Células Tronco, Instituto Carlos Chagas, ICC/Fiocruz-PR, Curitiba, Paraná, Brazil

dSaúde da Família, Secretaria Municipal de Saúde de Cambé, Cambé, Paraná, Brazil

eLaboratório de Protozoologia Experimental, Universidade Estadual de Londrina, Londrina, Paraná, Brazil

fLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou, Fundação

Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil

ABSTRACT

Dengue virus (DV) infection can cause either a self-limiting flu-like

dis-ease or a threatening hemorrhage that may evolve to shock and death. A variety of

cell types, such as dendritic cells, monocytes, and B cells, can be infected by DV.

However, despite the role of T lymphocytes in the control of DV replication, there

remains a paucity of information on possible DV-T cell interactions during the

dis-ease course. In the present study, we have demonstrated that primary human naive

CD4

and CD8

T cells are permissive for DV infection. Importantly, both T cell

sub-types support viral replication and secrete viable virus particles. DV infection triggers

the activation of both CD4

and CD8

T lymphocytes, but preactivation of T cells

reduces the susceptibility of T cells to DV infection. Interestingly, the

cytotoxicity-inducing protein granzyme A is highly secreted by human CD4

but not CD8

T

cells after exposure to DV

in vitro

. Additionally, using annexin V and polycaspase

as-says, we have demonstrated that T lymphocytes, in contrast to monocytes, are

resis-tant to DV-induced apoptosis. Strikingly, both CD4

and CD8

T cells were found to

be infected with DV in acutely infected dengue patients. Together, these results

show that T cells are permissive for DV infection

in vitro

and

in vivo

, suggesting that

this cell population may be a viral reservoir during the acute phase of the disease.

IMPORTANCE

Infection by dengue virus (DV) causes a flu-like disease that can

evolve to severe hemorrhaging and death. T lymphocytes are important cells that

regulate antibody secretion by B cells and trigger the death of infected cells.

How-ever, little is known about the direct interaction between DV and T lymphocytes.

Here, we show that T lymphocytes from healthy donors are susceptible to infection

by DV, leading to cell activation. Additionally, T cells seem to be resistant to

DV-induced apoptosis, suggesting a potential role as a viral reservoir in humans. Finally,

we show that both CD4

and CD8

T lymphocytes from acutely infected DV

pa-tients are infected by DV. Our results raise new questions about DV pathogenesis

and vaccine development.

KEYWORDS

dengue virus, replication, T lymphocytes

D

engue virus (DV) is the most prevalent arthropod-borne virus in the tropical and

subtropical areas of the world. Infection by any of the four serologically related

DVs (serotypes 1, 2, 3, and 4 [DV1 to DV4]) causes a wide range of clinical presentations,

from a flu-like disease to severe hemorrhaging that can evolve to shock and death (1).

Received21 December 2017Accepted23 February 2018

Accepted manuscript posted online7 March 2018

CitationSilveira GF, Wowk PF, Cataneo AHD, dos Santos PF, Delgobo M, Stimamiglio MA, Lo Sarzi M, Thomazelli APFS, Conchon-Costa I, Pavanelli WR, Antonelli LRV, Báfica A, Mansur DS, dos Santos CND, Bordignon J. 2018. Human T lymphocytes are permissive for dengue virus replication. J Virol 92:e02181-17.https://doi .org/10.1128/JVI.02181-17.

EditorMichael S. Diamond, Washington University School of Medicine Copyright© 2018 American Society for Microbiology.All Rights Reserved. Address correspondence to Claudia N. Duarte dos Santos, clsantos@fiocruz.br, or Juliano Bordignon, juliano.bordignon@fiocruz.br.

crossm

on November 6, 2019 by guest

http://jvi.asm.org/

(2)

In addition to viral factors, the pathogenesis of DV infection involves both innate and

adaptive immune responses (reviewed in references 2–4). Human cells, such as

mono-cytes, dendritic cells (DCs), and B cells, have been implicated in resistance to DV

infection. However, DV infection of these cells

in vitro

induces the secretion of

inflam-matory mediators, apoptosis, and polyclonal B cell activation, which contribute to

vascular leakage and DV-induced disease (5–8).

In addition to the above-mentioned cells, T lymphocytes are a major population

activated during dengue fever (9, 10). Previous reports have indicated that CD4

and

CD8

T cells play a role in the control of DV infection, mostly due to T cell-dependent

cytotoxicity against virus-infected cells (11, 12). In support of this concept, CD8

T cell

activation and proliferation are inversely correlated with dengue viremia and appear to

occur late in the course of DV infection (13). In contrast, low-affinity anti-DV T cells,

induced during secondary heterotypic infection, contribute to the high viral load and

intense inflammatory cytokine secretion observed in severe dengue cases (14).

More-over, activated CD4

and CD8

T cells have previously been found to be associated

with hemorrhagic disease (10, 13, 15). This suggests that while T cells may contribute

to controlling DV replication, they could also be involved in the pathogenesis of the

disease (3, 16). It is possible that DV directly infects human T cells and affects their

functions. It has been shown that human T leukemia cells and T cell lines can be

infected by DV serotype 2

in vitro

(17, 18) and in humanized mice (19), suggesting a

possible interaction between this flavivirus and human T cells. However, using flow

cytometry, two reports have demonstrated that human T cells are not infected by DV

in vitro

(20) or

ex vivo

(21). Nevertheless, whether DV directly interacts with primary

human T cells and the possible consequences of these interactions during DV infection

remain largely unknown.

To gain insight into possible DV-T cell interactions, we used a series of virology- and

immunology-based assays with primary human CD4

and CD8

T cells exposed to DV

serotypes 1 to 4. We observed that naive primary human T lymphocytes (CD4

and

CD8

) are permissive for DV infection and support viral replication, as well as the

synthesis of infectious virus particles. Additionally, after infection by DV, T lymphocytes

became activated and CD4

, but not CD8

, T cells secreted granzyme A (GzmA).

Despite being infected by DV, T lymphocytes were resistant to DV-induced apoptosis.

Additionally, using peripheral blood mononuclear cells (PBMCs) from acutely infected

dengue patients, we confirmed the susceptibility of CD4

and CD8

T cells to DV.

Together, our observations reveal a novel DV-host interaction that could contribute to

the understanding of dengue pathogenesis.

RESULTS

DV infects and replicates in CD4

and CD8

T lymphocytes through interaction

with the heparan sulfate moiety.

Because dengue fever patients have previously

been shown to display enhanced T cell activation (10, 13, 15), we first asked whether

DV directly interacts with T lymphocytes. For this assessment, we infected PBMCs with

different multiplicities of infection (MOIs) of DV3 and observed that CD4

and CD8

T

cells are susceptible to dengue virus infection (Fig. 1). In addition, kinetic experiments

using PBMCs from healthy donors confirmed the infection of CD4

and CD8

T

lymphocytes by DV3 (see Fig. S1 in the supplemental material). Thus, PBMCs from

healthy donors were exposed to the four DV serotypes (MOI of 10) and, after 5 days

postinfection, virus infection was measured by means of intracellular staining of the

virus envelope protein through flow cytometry (22). As previously shown (7, 23, 24), B

lymphocytes (CD19

) and monocytes (CD14

) were infected by DV serotypes 1 to 4

(Fig. S2A, D, and E). Similarly, CD4

and CD8

T cells were found to be infected by the

four DV serotypes (Fig. S2A to C). Furthermore, when purified CD4

and CD8

T cell

populations from 6 healthy donors (Fig. S2G and H) were infected with DV, similar

results were observed (Fig. 2A to E). It is noteworthy that confocal microscopy of

purified T cell populations exposed to DV confirmed that CD4

and CD8

T

lympho-Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

(3)

cytes were infected by DV (Fig. 2D and E). All DV serotypes presented similar levels of

infectivity in T cells (Fig. 2B and C).

Next, to gain insight into the possible host-expressed molecules involved in DV

binding in T cells, we examined the heparan sulfate (HS) moiety, which has been

characterized as a mediator of DV binding and entry in several cell lines (25–27).

Preexposure of DV to heparin, an inhibitor of host HS-virus interactions, led to

de-creased virus infectivity in CD4

and CD8

T cells in a dose-dependent manner (Fig. 2F

and G). Similarly, treatment of CD4

and CD8

T cells with heparinase III, an

HS-cleaving enzyme, reduced DV infectivity (Fig. 2H and I). These results suggest that HS

moieties participate in DV binding to human T cells.

We next investigated whether T cells support DV replication. Using a focus-forming

assay (Fig. 2J and M), reverse transcription-quantitative PCR (RT-qPCR) for the NS3 gene

FIG 1Infection of CD4⫹and CD8T lymphocytes with different MOIs of DV3. (A) Representative flow cytometry density plot data showing the results for mock infection and infection of CD4⫹and CD8T lymphocytes (4G2) with DV3 (strain 98) at MOIs of 1, 10, and 100, 5 days postinfection. (B and C) Bars represent the average frequencies of mock infection (circles) and DV3 infection (squares) of CD4⫹(B) and CD8(C) T cells (six different healthy donors).*,P0.05 compared to the results for mock-infected controls.

on November 6, 2019 by guest

http://jvi.asm.org/

[image:3.594.40.428.78.523.2]
(4)

Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

(5)

in infected cells (Fig. 2K and N), and an enzyme-linked immunosorbent assay (ELISA) of

the secretion of NS1 into the cell culture supernatant (Fig. 2L and O), we observed that

purified CD4

or CD8

human T lymphocytes support active replication of DV.

More-over, the staining of PBMCs infected by DV using an additional in-house-made

mono-clonal antibody (MAb) against NS3 [1722-1B; IgG1(

)] suggested that DV replicates in

CD4

and CD8

T lymphocytes (Fig. 3). Together, these results indicate that human

CD4

and CD8

T cells are susceptible to infection with DV serotypes 1 to 4 and

support virus replication. Additionally, when PBMCs from 16 healthy donors were

exposed to DV1 to DV4

in vitro

, CD8

T cells were found to be more susceptible to DV

infection than CD4

T lymphocytes (Fig. 4). In contrast, no staining was detected when

cells were exposed to gamma-irradiated DV1 to DV4 (Fig. 5).

DV infection activates resting T cells, which secrete granzyme A but do not

undergo apoptosis.

It has been previously shown that T cells are activated by means

of CD69 expression during severe dengue fever in children (10). To test whether T

lymphocytes are directly activated by DV infection, PBMCs were exposed to DV

serotype 3 for 5 days and stained for the expression of the activation markers CD69,

CD38, and HLA-DR. DV3 infection increased the frequencies of CD69

, CD38

, and

HLA-DR

expression on CD4

and CD8

T cells (Fig. 6) in infected and noninfected

cells. Similar results were observed when cell cultures were exposed to different DV

serotypes (Fig. S3). Also, not all infected T cells expressed activation markers (Fig. 6;

Fig. S3).

We next asked whether the activation status of T lymphocytes could modulate viral

infectivity. Indeed, stimulation of enriched lymphocyte cultures upon polyclonal

stim-ulation (anti-CD3/anti-CD28 MAb) impaired DV infection in both CD4

and CD8

T

lymphocytes (Fig. 7A and B). Thus, infection of purified CD69

and CD69

cells

confirmed that the later CD4

and CD8

T cells were more susceptible to DV infection

than CD69

T cells (Fig. 7C to F).

It was also described that T cell activation led to the release of granzyme serine

proteases and the pore-forming protein perforin (28), thus triggering the apoptosis of

target cells. GzmA (Fig. 8A) and perforin (Fig. 8B) were secreted by DV-infected PBMCs.

Next, we infected purified CD4

and CD8

T cells to determine the sources of GzmA

and perforin. Interestingly, CD4

T lymphocytes were the main source of GzmA

secretion after DV infection (Fig. 8C to F), whereas neither CD4

nor CD8

T cells were

the source of human perforin (Fig. S4).

DV infection triggers apoptosis in a wide range of cells, including dendritic cells,

neurons, and hepatocytes (22, 29). We next asked if DV could also trigger T cell

apoptosis. Programmed cell death in DV-exposed PBMC cultures was examined by

polycaspase staining and flow cytometry. In contrast to monocytes and dendritic cells

(22), CD4

and CD8

T lymphocytes did not undergo apoptosis following DV infection

(Fig. 9A). Further analyses confirmed the lack of correlation between infection and

FIG 2Human lymphocytes are susceptible to DV infection and replication. (A) Representative flow cytometry density plots of purified cells showing the frequencies of CD4⫹and CD8T cells infected by DV. The number within each box refers to the frequency of cells within each gate. (B and C) Average frequencies of CD4⫹and CD8T cell infection by the four DV serotypes. Mock infection (circles) and DV1 BR90 (squares), DV2 265 (triangles), DV3 98 (inverted triangles), and DV4 360 (diamonds) infection. Bars show the mean values for samples from six healthy donors.*,Pⱕ0.05 compared to the results for infection by four DV serotypes. (D and E) Confocal fluorescence microscopy of CD4⫹ and CD8⫹T cells labeled for DNA (DAPI; blue), DV (anti-E protein MAb; red), and immunophenotyping markers (anti-CD4 or anti-CD8 MAb; green). Scale bar⫽10␮m. (A, D, E) Data are representative of six independent experiments. (F and G) Flow cytometry data indicating the average frequencies of DV-infected CD4⫹(F) and CD8(G) T lymphocytes (CD14-depleted cells from six healthy donors) after virus treatment with different concentrations of heparin (2 to 20␮g). (H and I) Average frequencies, using a flow cytometry assay, of CD4⫹(H) and CD8(I) T lymphocytes infected with DV1 to DV4 after cell treatment with different concentrations of heparinase III (0.5 to 5.0 IU) and infection with the four DV serotypes. Data represent the mean values⫾standard errors of the means (SEM) for cells from six healthy donors.*,Pⱕ0.05 compared to the results for mock-infected controls. (J and M) DV progeny in cell culture supernatants from purified CD4⫹(J) and CD8(M) T lymphocytes infected with the four DV serotypes were quantified using a focus-forming assay in C6/36 cells. (K and N) DV replication on CD4⫹(K) and CD8(N) T lymphocytes (purified via cell sorting) was determined by real-time PCR assay. Quantification of DV nonstructural protein 3 (NS3) gene mRNA, normalized to the housekeeping gene18S, for comparison of the levels in infected cells and mock-infected cells. (L and O) Qualitative determination of the levels of DV nonstructural protein 1 (NS1) in cell culture supernatants of purified CD4⫹(L) and CD8⫹ (O) T lymphocytes infected by DV by using a capture ELISA from PanBio (values⬎11 indicate NS1 secretion). Mock infected (circles) and DV1 BR90 (squares), DV2 265 (triangles), DV3 98 (inverted triangles), and DV4 360 (diamonds) infected. Bars show the mean values for cells from six healthy donors.*,Pⱕ0.05 compared to the results for infection by four DV serotypes.

on November 6, 2019 by guest

http://jvi.asm.org/

(6)

apoptosis in T cells (and in CD19

B cells), as well as the expected positive correlation

in CD14

monocytes (Fig. 9B to E). Similar results were obtained when annexin

V–7-aminoactinomycin D (7-AAD) staining was used to quantify DV-induced apoptosis

in T cells (Fig. S5A to D). Together, these data suggest that upon infection, resting T cells

are activated by DV but do not undergo apoptosis, an important process that controls

viral replication (8). Additionally, because DV-exposed T cells appeared to be more

resistant to apoptosis than DV-infected monocytes, we asked whether DV actively

inhibits the apoptosis of T lymphocytes. To do so, PBMC cultures were infected with

DV4 and, 4 days later, exposed to low doses of the apoptosis inducer staurosporine

(STS) (30). The results showed that DV failed to prevent STS-induced annexin V

expression by human CD4

and CD8

T cells (Fig. 9F and G). These results suggest that

DV does not actively inhibit STS-induced apoptosis in human T lymphocytes.

FIG 3Detection of CD4⫹and CD8⫹T lymphocyte infection using anti-E and anti-NS3 MAbs. Representative flow cytometry density plot data showing CD4⫹(A) and CD8(C) T lymphocyte infection with DV3 (strain 98) and mock infection after 5 days postinfection, using anti-GFP (isotype control), anti-E (4G2), and anti-NS3 (1722-1B) antibodies. (B and D) Bars represent the average frequencies of CD4⫹(B) and CD8⫹(D) T cell (samples from six healthy donors) infection with DV3 (squares) and mock infection (circles) after staining with anti-GFP (isotype control), anti-E (4G2), and anti-NS3 (1722-1B) antibodies.␣,P0.05 comparing mock infection to DV3 infection using the same antibody;␤,P0.05 comparing staining with 4G2 and 1722-1B to the results for the isotype control.

Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

[image:6.594.44.488.73.512.2]
(7)

CD4

and CD8

T lymphocytes are infected with DV in patients in the acute

phase.

Although the results described above indicated that DV serotypes 1 to 4 directly

interact with and replicate in T cells

in vitro

, we asked whether these lymphocytes were

also infected during dengue fever. Thus, we collected PBMCs and serum samples from

13 patients with clinical signs of dengue fever in an area where DV is endemic. Serum

samples were used for virus isolation in C6/36 cells, followed by RT-PCR confirmation.

Six of the 13 patients were positive for DV. In the positive samples, viremia was

measured by a focus-forming assay in C6/36 cells in focus-forming units per ml

(FFU

C6/36

/ml), with values between 2.2

10

4

and 2.6

10

5

. Table 1 summarizes the

data from patient samples used in the assay. To determine whether CD4

and CD8

T

cells from patients with dengue fever were infected with DV, PBMCs were stained with

two different monoclonal antibodies, anti-DV E protein MAb (clone 4G2) or anti-DV NS3

protein MAb (clone 1722-1B). Flow-cytometric analysis showed that human CD4

and

CD8

T cells from acutely infected DV patients (positive for viral isolation and by

RT-PCR) were positively stained with anti-DV E and DV NS3 MAbs (Fig. 10A to D). As

previously demonstrated, monocytes (CD14

) and B cells (CD19

) were also infected

by DV (Fig. 10E to H) (7, 8, 20). Together, these data suggest that during acute dengue

fever, DV infects T cells.

DISCUSSION

DV infects a wide range of cell types, including monocytes, dendritic cells, and B

lymphocytes. The infection of those cells induces the activation and secretion of

cytokines and antibodies, which can contribute to the immunopathogenesis of dengue

(6–8, 20, 23, 24, 31). Despite the recognized role of T lymphocytes in the control of DV

replication and also in the pathogenesis of hemorrhagic disease, there is controversy

regarding the susceptibility of T cells to DV infection (11, 12, 15, 17, 24). In previous

studies, T lymphocytes obtained from PBMCs or splenic mononuclear cells from healthy

donors were not susceptible to DV2 infection (20, 24). In contrast, DV2 (strain 16681)

was able to infect and replicate in T cell lineages (17, 18). Furthermore, human T cells

were shown to be infected by DV2 (strain K0049) in a humanized mouse model (19),

indicating a possible interaction between DV and T cells

in vivo

.

In the present study, using several immunology- and virology-based techniques, we

found that the four DV serotypes can infect and replicate in primary human T

lympho-cytes. However, despite using cell sorting to purify cultures of T lymphocytes, we could

not exclude the contribution of DV infection of monocytes/dendritic cells in the virus

yield detected in the cell culture supernatant. Furthermore, we observed that HS

moieties contribute to the binding of DV to T cells, as has been demonstrated

previously for other cell lines (25, 32). Finally, using two different monoclonal

antibod-ies against DV (anti-E protein and anti-NS3 protein MAbs), we demonstrated that both

FIG 4Differential susceptibilities of CD4⫹and CD8⫹T lymphocytes to DV infection. Bars represent the average frequencies of CD4⫹and CD8T lymphocytes infected by DV1 (A), DV2 (B), DV3 (C), and DV4 (D) at an MOI of 10. After 5 days, cells were recovered and stained for phenotyping markers (CD3, CD4, and CD8) and for dengue virus E protein (4G2 antibody). Data are from 24 PBMC samples (representing 16 different healthy donors) infected with four DV serotypes.***,Pⱕ0.001 comparing the levels of infection of CD8⫹to that of CD4⫹T lymphocytes.

on November 6, 2019 by guest

http://jvi.asm.org/

[image:7.594.44.443.70.205.2]
(8)

CD4

and CD8

T cells are infected by DV in acute-phase patients, confirming the data

obtained in

in vitro

experiments.

We have observed that DV infection triggers T cell activation and that activated cells

become resistant to DV virus infection. It is well established that T lymphocytes are

highly activated in dengue hemorrhagic fever (DHF) patients compared to their level of

activation in patients with dengue fever, suggesting a role for T cell activation in the

pathogenesis of DV hemorrhagic fever (10). Also, the activation and proliferation of

CD8

T cells seem to occur late in the course of DV infection and are inversely

correlated with dengue viremia (13). In addition, T cell activation could impair their

susceptibility to infection. For instance, resting T cells are susceptible to human

immunodeficiency virus type 1 (HIV-1); nevertheless, virus integration is dependent on

T cell activation (33). Furthermore, for myxoma virus, T cell activation is required to

FIG 5Inactivated DV does not infect human T cells. (A) Representative flow cytometry density plot data showing human CD4⫹ and CD8T lymphocyte infection (MOI of 10) with DV3 98 and gamma-irradiated DV3 98 (iDV3) and mock infection. The number within each box refers to the frequency of cells within each gate. (B and C) Average percentages of CD4⫹(B) and CD8(C) T cells infected with four DV serotypes and the respective gamma-irradiated strains in PBMC cultures after 5 days postinfection. Mock infection (circles) and infection with DV1 BR90 or inactivated DV1 BR90 (squares), DV2 265 or inactivated DV2 265 (triangles), DV3 98 or inactivated DV3 98 (inverted triangles), and DV4 360 or inactivated DV4 360 (diamond). Bars represent the mean values⫾SEM for cells from six healthy donors.*,Pⱕ0.05 compared to the results for mock controls and for inactivated DV.

Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

[image:8.594.49.365.74.471.2]
(9)

allow viral replication in T lymphocytes (34). Regarding DV infection, T lymphocyte

activation could trigger the secretion of inflammatory mediators, leading to a cytokine

storm (13, 15, 35). The serine proteases granzymes A, B, and K have been found at high

levels in the plasma of DV-infected patients (36). Moreover, dengue-specific CD4

T

cells with cytolytic activity were recently shown to play a role in the control of DV

infection

in vivo

(12). Here, we demonstrate that T cell activation triggered by DV

infection leads to the secretion of the serine protease GzmA by CD4

T cells. While

FIG 6DV infection activates T lymphocytes. (A) Representative flow cytometry density plot data showing DV3 infection (4G2⫹) and cellular activation (CD69⫹) of CD4and CD8T lymphocytes. (B to I) Average frequencies of CD4(B) and CD8(F) T cell infection with DV3 and levels of expression of activation markers CD69⫹(C and G), CD38(D and H), and HLA-DR(E and I) in CD4(B to E) and CD8(F to I) T lymphocytes. PBMC samples from six healthy donors were mock infected (circles) or infected with gamma-irradiated DV3 98 (iDV3; triangles) and DV3 98 (inverted triangles).␣,Pⱕ0.05 comparing the results for mock and DV3 infection;␤,Pⱕ0.05 comparing the results for iDV3 and DV3 infection.

on November 6, 2019 by guest

http://jvi.asm.org/

[image:9.594.46.493.79.579.2]
(10)

FIG 7Activated T lymphocytes are more resistant to DV infection. (A and B) Enriched T lymphocyte cultures (CD14⫹depleted) were stimulated overnight with anti-CD3 and anti-CD28 MAbs and infected with the four DV serotypes. After 5 days, cells were stained for anti-DV MAb (4G2⫹) and cellular markers (CD3⫹/CD4and CD3/CD8). Data show levels of T cell infection after stimulation with anti-GFP MAb (isotype control; circles) and anti-CD3/anti-CD28 MAb (squares).*,P0.05 compared to the results for nonactivated lymphocytes. (C to F) PBMCs were stimulated using anti-CD3/anti-CD28 MAbs, and activated (CD69⫹) and naive (CD69) T cells were purified by flow cytometry and infected with DV3 98 (MOI of 10) for 5 days. (C and E) Representative flow cytometry density plot data showing DV3 98 infection (4G2⫹) in purified CD69⫹(activated) and CD69⫺(nonactivated or naive) T cells. (D and F) Average frequencies of CD4⫹(D) and CD8(F) T cell infection with DV3 in activated (CD69) and naive (CD69) T cells. Mock (circles), gamma-irradiated DV3 98 (iDV3) (inverted

(Continued on next page)

Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

[image:10.594.42.530.63.654.2]
(11)

DV-infected PBMCs release both granzyme A and perforin, we could not exclude the

possibility that natural killer cells were the source of those mediators, especially

perforin.

It has been previously demonstrated that DV infection triggers apoptosis in a

number of cell types, such as hepatocytes and endothelial cells, contributing to the

hepatic damage and hemorrhagic manifestations observed in severe dengue cases (29,

37, 38). DV also triggers the apoptosis of monocytes and dendritic cells, which impacts

the immune response to the infection (8, 22, 39). Apoptosis has also been detected in

leukocytes and microvascular endothelial cells in pulmonary and intestinal tissue, which

could be associated with vascular plasma leakage (29). In contrast, we show here that

CD4

and CD8

T lymphocytes were resistant to DV-induced apoptosis, which could

suggest a viral escape mechanism. Extending cell survival allows viruses to replicate

and mature (reviewed in reference 40). For instance, HIV, which infects CD4

T cells,

FIG 7Legend (Continued)

triangles), and DV3 98 (diamonds) infected.␣,Pⱕ0.05 comparing the results for mock and DV3 infection;␤,Pⱕ0.05 comparing the results for iDV3 and DV3 infection;␥,Pⱕ0.05 comparing the results for infection of CD69⫺and CD69cells.

FIG 8DV infection of CD4⫹T lymphocytes triggers the secretion of granzyme A. (A and B) Concentrations of granzyme A (A) and perforin (B) in PBMCs infected with four DV serotypes. Mock infected (circles) and DV1 BR90 (squares), DV2 265 (triangles), DV3 98 (inverted triangles), and DV4 360 (diamonds) infected.*,Pⱕ0.05 compared to the results for infection by the four DV serotypes. (C to F) Purified CD4⫹(circles) and CD8T cells (squares) were infected with DV1 (C), DV2 (D), DV3 (E), and DV4 (F), and granzyme A was measured in the cell culture supernatants after 5 days. Bars show the mean values for cells from six healthy donors infected with strains of the four DV serotypes.*,Pⱕ0.05 compared to the results for infection by DV.

on November 6, 2019 by guest

http://jvi.asm.org/

[image:11.594.43.409.71.435.2]
(12)

FIG 9DV infection does not modulate lymphocyte apoptosis. (A) Representative flow cytometry density plot data for PBMCs infected with DV3 98 (4G2⫹) and polycaspase stained. (B to E) Pearson correlation analysis between the percentages of infected CD4T cells (B), CD8T

(Continued on next page)

Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

[image:12.594.45.485.75.714.2]
(13)

displays different strategies to avoid T cell apoptosis. As shown using Jurkat T cells, the

HIV-1 protein Tat inhibits TRAIL-induced apoptosis (41), while HIV-1 Nef blocks Fas- and

tumor necrosis factor alpha (TNF-

)-induced apoptosis (42). Additionally, T cells from

hepatitis C virus HCV-/HIV-coinfected patients have been shown to be more resistant to

apoptosis than T lymphocytes from HIV-infected patients (43). The same study

dem-onstrated that HCV-infected CD4

T cells are more resistant to HIV-induced cell death.

In conclusion, our data demonstrate that human CD4

and CD8

T lymphocytes are

susceptible to DV infection

in vitro

, which triggers T cell activation and GzmA secretion

by CD4

T cells. Furthermore, T lymphocytes are resistant to DV-induced apoptosis.

Additionally, once human CD4

and CD8

T cells are infected in acute-phase patients,

we hypothesize that T lymphocytes serve as viral reservoirs during DV infection,

contributing to viremia and T cell activation. Finally, our study suggests an additional

role for CD4

and CD8

T lymphocytes in DV pathogenesis that could influence

vaccine development strategies.

MATERIALS AND METHODS

Ethics statement.Blood samples were obtained using a surface venipuncture procedure after DV-suspected or healthy donors provided written consent. In the case of children, parents provided written consent. All blood samples were blindly coded to ensure anonymity of the patients or healthy donors. Finally, the study protocol was approved by the Committee of Research Ethics from FIOCRUZ (CEP/FIOCRUZ) under the numbers 514/09 and CAAE: 49931415.7.1001.5248/Fiocruz.

Primary cell cultures.Blood samples were collected from 33 clinically healthy adult donors (15 males and 18 females) with a mean age of 29.97⫾4.21 years and no history of DV infection (IgM/IgG negative using an Alere enzyme-linked immunosorbent assay [ELISA]) in the city of Curitiba (25°25=47⬙S, 49°16=19⬙W), Paraná State, South Brazil. Additionally, blood samples from patients with suspected DV infection (Table 1) were obtained in the city of Cambé (23°16=33⬙S, 51°16=40⬙W), Paraná State, South Brazil, where DV infection is endemic. From these samples, PBMCs were obtained by density gradient separation with lymphocyte separation medium (Lonza). Enriched lymphocyte cultures (CD14⫹depleted) were purified by magnetic immunosorting (negative selection) with anti-CD14 Ab beads (Miltenyi Biotec) or from the non-plastic-adherent fraction of PBMCs. To perform the flow cytometry cell-sorting separa-tion (FACSAria II; BD Biosciences), PBMCs were labeled with anti-CD3-phycoerythrin (PE) MAb (clone HIT3a), anti-CD14-fluorescein isothiocyanate (FITC) MAb (clone M5E2), anti-CD8-peridinin chlorophyll protein (PerCP) MAb (clone SK1), anti-CD19-PE-Cy7 MAb (clone SJ25C1), and anti-CD4-allophycocyanin (APC) MAb (clone RPA-T4) (BD Biosciences) or their respective isotype controls. PBMCs, enriched lymphocytes (CD14⫹depleted) or cultures purified by cell sorting were maintained in RPMI 1640 medium (Lonza) containing 100 IU/ml penicillin (Gibco), 100␮g/ml streptomycin (Gibco), 2 mML-glutamine (Gibco), 2.5␮g/ml amphotericin B (Gibco), and 10% fetal bovine serum (FBS) and incubated at 37°C with 5% CO2. The use of PBMCs, enriched lymphocytes (CD14⫹depleted) or cell-purified T cells was defined

based on the main objectives of each experiment and specified accordingly.

Viral stocks and infection of T lymphocytes.DV infection assays were performed with all four serotypes. Two strains, DV1/BR/90 (GenBank accession numberS64849.1), first described by Desprès and colleagues in 1993 (44), and DV4/TVP360, kindly provided by Ricardo Galler, Fiocruz/RJ, Brazil (GenBank accession numberKU513442.1), were laboratory-adapted DV strains with a high number of passages in cell culture. Additionally, two DV strains that were recently isolated from acutely infected patients and maintained for 3 or 4 passages in C6/36 cells were also included in this study. DV2/ICC265 was isolated from a patient who acquired dengue fever in 2009 in the state of Paraná, Brazil. BR DV3/98-04 (GenBank accession numberEF629368.1), first described by Nogueira and colleagues in 2008 (45), was isolated from a dengue fever patient in Rio Branco (9°58=29⬙S, 67°48=36⬙W), Acre, northern Brazil, in 2004. We refer to these strains herein as DV1 BR90, DV2 265, DV3 98, and DV4 360.

Viral stocks were obtained from clarified supernatant from larval Aedes albopictus (C6/36) cells infected with the different DV serotypes at a multiplicity of infection (MOI) between 0.1 and 1. The samples were stored at⫺80°C. The viral stock concentrations were obtained using a focus-forming-assay technique in the C6/36 cell line (46). A negative-control infection culture (mock) was conducted in parallel using noninfected C6/36 cell supernatant. Gamma-irradiated DV1 to DV4 were also used as controls in some experiments.

FIG 9Legend (Continued)

cells (C), and B cells, i.e., CD19⫹(D) or CD14(E) monocytes, and polycaspase staining. The data represent fold induction of infection and apoptosis related to the results for the mock-infected control. PBMCs from six healthy donors were infected with four DV serotypes. (F and G) PBMCs from healthy donors were infected with DV4 360 for 4 days and treated with staurosporine (STS) for an additional 24 h. Average frequencies of CD4⫹and CD8T cell apoptosis after staurosporine treatment (200 nM) in DV-infected cells and uninfected controls. Bars show the mean values for PBMCs from six healthy donors infected with DV4 360. The dotted-and-dashed lines (untreated) indicate the level of apoptosis of mock-treated control lymphocytes.*,Pⱕ0.05 comparing the results for DV4 infection to the results for STS treatment or STS treatment plus DV4 infection by one-way ANOVA.

on November 6, 2019 by guest

http://jvi.asm.org/

(14)

FIG 10CD4⫹and CD8T lymphocytes are naturally infected by DV in acute-phase patients. (A, C, E, and G) Representative flow cytometry density data showing CD4⫹(A) and CD8(C) T lymphocyte, B cell (CD19) (E), and monocyte (CD14⫹)(G)

(Continued on next page)

Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

[image:14.594.45.425.66.697.2]
(15)

For DV infection, 5.0⫻105human cells were incubated with viral stocks (MOI of 10) or

gamma-irradiated virus or mock infected in RPMI without FBS for 2 h at 37°C. Later, the cultures were centrifuged at 3,000⫻gfor 60 s. The supernatant was discarded, and the cells were recovered with 0.5 ml of RPMI 1640 medium (Lonza) supplemented with 100 IU/ml penicillin (Gibco), 100␮g/ml streptomycin (Gibco), 2 mML-glutamine (Gibco), 2.5␮g/ml amphotericin B (Gibco), and 10% FBS. The cell suspensions were incubated for 5 days at 37°C under 5% CO2in 24-well plates. The infected cells were recovered and used

for further experiments.

Immunophenotyping and DV intracellular labeling.For immunophenotypic and/or viral protein labeling, cell culture plates were centrifuged at 1,500⫻gfor 60 s. The supernatants were stored at

⫺80°C for further analysis, and the cells were recovered with 100␮l of blocking buffer (phosphate-buffered saline [PBS] plus 5% FBS and 1% AB human serum [Lonza]) for 20 min at room temperature. After washing with PBS, the cells were recovered in 100 ␮l Cytofix/Cytoperm (BD Biosciences) and incubated for 20 min at room temperature, protected from light. After incubation, the cells were washed once with 100␮l of Perm/Wash solution (BD Biosciences), the plate was centrifuged at 1,500⫻gfor 2 min, and the supernatant was discarded. The cells were mixed with 100␮l of an anti-flavivirus E protein MAb (4G2 [ATCC HB-112]; 10␮g/ml) at 1:100 (vol/vol) in Perm/Wash or 100␮l of anti-DV nonstructural protein 3 (NS3) MAb (1722-1B; 10␮g/ml) at 1:100 (vol/vol) in Perm/Wash and incubated for 30 min at 37°C and 5% CO2. After incubation, the cells were washed with 100␮l Perm/Wash solution, mixed with

100␮l of Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen) at 1:100 (vol/vol) in Perm/Wash, and incubated for 30 min at 37°C and 5% CO2. Then, the cells were washed again with PBS and incubated

with 50␮l of a MAb mixture diluted 1:50 (vol/vol) in PBS, including the following MAbs: anti-CD14-PE MAb (clone M5E2), anti-CD8-PerCP MAb (clone SK1), anti-CD19-PE-Cy7 MAb (clone SJ25C1), anti-CD4-APC MAb (clone RPA-T4), anti-CD3-anti-CD4-APC-Cy7 MAb (clone SK7) (all from BD Biosciences), and their respective isotype controls. After incubation for 30 min at 37°C (5% CO2), the cells were washed and

recovered with 200␮l of PBS. The cell suspensions were analyzed by flow cytometry on a FACSCanto II instrument (BD Biosciences).

For confocal microscopy, one aliquot of labeled cells (as described above) was collected. The cells were centrifuged at 1,500⫻gfor 2 min, the supernatant was discarded, and the cells were recovered in 50␮l of PBS containing 300 nM DAPI (4=,6-diamidino-2-phenylindole; Molecular Probes) and incubated for 30 min at 37°C. Cells were washed 3 times with PBS, added to a glass slide coated with 10% poly-L-lysine (Sigma-Aldrich), and incubated for 5 min at 37°C. After incubation, the cells were washed in PBS, the excess was removed by pipetting, a glass coverslip was added, and the edges were sealed. The images were analyzed using a Leica TCS SP5 confocal microscope (Leica Microsystems).

DV NS1 detection, focus-forming assay, and RT-qPCR.The supernatants from PBMCs and purified cultures of T lymphocytes were analyzed for the presence of DV nonstructural protein 1 (NS1) using the Panbio dengue early ELISA (Alere) according to the manufacturer’s instructions. The reaction absorbance was read at wavelengths of 600 and 650 nm to calculate the index. Index values (PanBio units) were

FIG 10Legend (Continued)

[image:15.594.42.372.83.232.2]

infection by DV1 in PBMCs from an acute-phase patient. Lymphocyte infection was observed by labeling the viral proteins with anti-flavivirus E protein MAb (4G2), anti-DV NS3 MAb (1722-1B), or an isotype control (anti-GFP MAb). The number within each box refers to the frequency of cells within each gate. Phenotype staining was performed using anti-CD3, anti-CD4, anti-CD8, anti-CD19, and anti-CD14 MAbs. Cell infection was shown using PBMCs from a patient negative for DV infection (PBMC#13) and a patient infected with DV1 (PBMC#3). (B, D, F, and H) Average frequencies of CD4⫹(B) and CD8⫹ (D) T lymphocytes, B cells (F), and monocytes (H) infected by DV (anti-DV NS3 and anti-DV E MAbs) in PBMCs from seven negative (circles) and six DV-infected patients (squares).␣,Pⱕ0.05 comparing the results for anti-DV MAb (4G2 or 1722-1B) staining in PBMCs from DV-infected and noninfected patients;␤,Pⱕ0.05 comparing the results for staining with 4G2 or 1722-1B and the isotype control (anti-GFP MAb).

TABLE 1Clinical characterization of human patient samples

Sample Gendera Age (yr)

Virus isolation (IF)b

RT-PCR result

Viremia (FFUC6/36/ml)

PBMC#1 F 29 Pos DV1 3.9⫻104

PBMC#3 F Pos DV1 2.6⫻105

PBMC#4 M 23 Pos DV1 4.7⫻104

PBMC#6 M 28 Neg Neg ND

PBMC#7 M 53 ND DV1 ND

PBMC#8 M 55 Neg Neg ND

PBMC#11 F 36 Neg Neg ND

PBMC#13 F 13 Neg Neg ND

PBMC#14 F 25 Neg Neg ND

PBMC#16 M 53 Pos DV1 2.2⫻104

PBMC#18 F 38 Pos DV1 1.0⫻105

PBMC#22 M 14 Neg Neg ND

PBMC#27 F 51 ND Neg ND

aM, male; F, female.

bPos, positive; Neg, negative; ND, not determined; IF, immunofluorescence.

on November 6, 2019 by guest

http://jvi.asm.org/

(16)

expressed according to the cutoff to determine the presence (⬎11 units) or absence (⬍9 units) of the NS1 protein in the culture supernatant.

Supernatants from cell cultures (PBMCs and purified T cells) were further used to quantitate the DV progeny using a focus-forming assay in C6/36 cells (FFUC6/36/ml), following the procedure adapted from

Gould and Clegg (46). Finally, DV replication was measured in total RNA extracted from frozen/thawed purified T lymphocytes using the RNeasy minikit (Qiagen) according to the manufacturer’s recommen-dations. RT-qPCR with the DV NS3 gene as a target was also performed. For RT-qPCR, cDNA was obtained using 5␮g of total RNA, random primers (4 pmol/reaction mixture; Invitrogen), and 1␮l of ImProm-II reverse transcriptase enzyme (Promega) for 2 h at 42°C. Quantitative PCR was performed with SYBR green master mix (Applied Biosystems), 0.5 ng/␮l of cDNA, and 4 pmol/reaction mixture of specific primers (Table 2). The cycling regimen was as follows: 50°C for 2 min and 96°C for 10 min, followed by 40 cycles of 96°C for 15 s, 59°C for 30 s, and 72°C for 1 min. The constitutively expressed18Sgene was used for the normalization and quantification of the amplification reaction products. Gene expression was calculated by the cycle threshold (2⫺ΔΔCT) method adapted from Livak and Schmittgen (47).

DV binding to T lymphocytes.Viral suspensions were incubated with heparin (Vacuplast). Briefly, an amount of 5.0⫻106FFU

C6/36of a DV suspension of each of the four serotypes in Leibovitz’s L-15 medium

(L15; Thermo Fisher Scientific) (0.1 ml) was incubated with 2, 5, 10, or 20␮g/ml heparin or with PBS (positive control). After 2 h at 37°C, each DV-plus-heparin mixture was used as an inoculum for enriched lymphocyte cultures (CD14⫹depleted) as described above in “Viral stocks and infection of T lympho-cytes.”

Additionally, enriched lymphocyte cultures (CD14⫹ depleted) were treated with heparinase III (Sigma), an enzyme that removes heparan sulfate (HS) residues from the cell surface. For this purpose, an amount of 5.0⫻105lymphocytes was treated with 0.5, 1.0, or 5.0 IU/ml heparinase III or with PBS

(positive control) in 0.1 ml of RPMI medium at 37°C for 2 h. After cell treatment with heparinase III, the cells were washed with PBS and infected as described above in “Viral stocks and infection of T lymphocytes.”

Lymphocyte cell death triggered by DV infection.After DV infection, lymphocyte cell death was analyzed using annexin V–7-aminoactinomycin D (7-AAD) or the detection of activated caspases. PBMCs (from healthy donors) were infected (MOI of 10) with the four DV serotypes as described above in “Viral stocks and infection of T lymphocytes.” After 5 days, the cells were separated into two populations. The first group was analyzed for the percentage of infection as described above in “Immunophenotyping and DV intracellular labeling” and for activated caspases using the Image-iT live red polycaspase detection kit (Life Technologies). Briefly, 5.0 ⫻ 105 PBMCs were recovered, washed with 100l of 1FLICA

(fluorochrome inhibitor of caspases), and incubated for 60 min at 37°C in 5% CO2protected from light.

After incubation, 100␮l of binding buffer was added, and the analysis was performed using a FACSCanto II flow cytometer.

To confirm the data on activated caspases, the second group of cells was stained with the annexin V:PE apoptosis detection kit I (BD Biosciences) as described by the manufacturer. Briefly, for annexin V, 5.0⫻105PBMCs were recovered, washed with 100l of binding buffer containing 5l of annexin V and

5␮l of 7-AAD, and incubated for 15 min at 37°C in 5% CO2, protected from light. After incubation, 100

␮l of binding buffer was added, and the cells were analyzed on a FACSCanto II flow cytometer. Additionally, 2⫻105PBMCs from healthy donors were infected (MOI of 5) with DV4 360 (stock in

C6/36 cells and titration in BHK-21 cells) and incubated at 37°C for 2 h. Then, the cells were spun, the viral inoculum was removed, and the cells were suspended in supplemented RPMI 1640 medium. The cells were incubated for 4 days before being treated with staurosporine (200 mM; Sigma-Aldrich) for 24 h and stained with anti-CD3-FITC MAb (clone UCHT1), anti-CD4-APC-Cy7 MAb (clone OKT4), anti-CD8-PE-Cy7 MAb (clone SK1; Biolegend), and anti-CD14-V450 MAb (clone M␸P9; BD Biosciences). Next, the cells were incubated with annexin V-APC (Immunotools) for 15 min protected from the light. The PBMCs were then washed in annexin binding buffer, and propidium iodide (BD Pharmingen) was added prior to data acquisition on a FACSVerse (BD Biosciences).

Lymphocyte activation after DV infection.To determine if lymphocyte infection by DV triggers the activation of these cells, PBMCs from clinically healthy donors (anti-DV IgM and IgG negative) were infected with DV for 5 days. After infection, lymphocyte activation was assessed by the expression of CD69 (anti-CD69-PerCP MAb; clone FN50), CD38 (anti-CD38-PE MAb; clone HB7), and HLA-DR (anti-HLA-DR-APC MAb; clone G46-6) (all antibodies from BD Biosciences). Additionally, DV infection of lympho-cytes was measured using the 4G2 antibody together with the phenotypic markers anti-CD3-APC-H7 MAb (clone SK7), anti-CD4-AmCyan MAb (clone RPA-T4), and anti-CD8-PE-Cy7 MAb (clone SK1) (all antibodies from BD Biosciences). Labeling was performed as described above in “Immunophenotyping and DV intracellular labeling.”

Furthermore, to evaluate the permissiveness of activated lymphocytes to DV infection, enriched lymphocyte cultures (CD14⫹depleted) were activated overnight using anti-CD28 MAb (clone CD28.2, 200 ng/well; BD Biosciences) and anti-CD3 MAb (clone HIT3a, 200 ng/well; BD Biosciences). As a control, enriched lymphocyte cultures were treated with an anti-green fluorescent protein (GFP) monoclonal antibody (made in-house). After activation, the cells were washed and infected with DV (MOI of 10) as previously described. After 5 days, the cells were stained using anti-CD3-APC-Cy7 MAb (clone SK7), anti-CD4-APC MAb (clone RPA-T4), anti-CD8-PerCP MAb (clone SK1), anti-CD69-PE MAb (clone FN50) (all antibodies from BD Biosciences), and anti-DV MAb (4G2) as described above in “Immunophenotyping and DV intracellular labeling.”

Also, activated T cells (from PBMC cultures) were obtained using anti-CD3/anti-CD28 MAbs, as described above. After overnight incubation, the cells were stained using CD69-PE MAb (clone FN50; BD

Biosci-Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

(17)

ences), and the nonactivated (CD69⫺) and activated (CD69) populations were purified using flow cytometry. Both populations were infected with DV3 (MOI of 10) or gamma-irradiated DV3 or mock infected for 5 days. After incubation, DV infection of lymphocytes was measured using 4G2 antibody together with the phenotypic markers anti-CD3-APC-Cy7 MAb (clone SK7), anti-CD4-APC MAb (clone RPA-T4), and anti-CD8-PerCP MAb (clone SK1) (phenotypic markers were from BD Biosciences). Labeling was performed as described above in “Immunophenotyping and DV intracellular labeling.”

Granzyme A and perforin detection.The supernatants from PBMCs and purified cultures of T lymphocytes infected by DV were analyzed for the presence of granzyme A and perforin using the cytometric bead array human granzyme A flex set (BD Biosciences) and perforin human ELISA kit (Abcam), respectively, according to the manufacturer’s instructions.

Permissiveness of T lymphocytes to DV infection in acute-phase DV patients.To confirm the permissiveness of T lymphocytes to DV infection in acute-phase DV patients, blood samples from DV patients were analyzed. The samples were obtained from patients suspected to be infected by dengue virus (until 7 days after the beginning of the symptoms) based on clinical examination in the city of Cambé (23°16=33⬙S, 51°16=40⬙W), North Region of Paraná State, South Brazil. Blood and serum samples were collected with the patients’ consent, as approved by the FIOCRUZ Research Ethics Committee (CAAE: 49931415.7.1001.5248). Serum samples were used to confirm the DV diagnosis by virus isolation in C6/36 cells, followed by one-step RT-PCR as previously described (48). For two patients (PBMC#27 and PBMC#7), we could not obtain serum, and dengue diagnosis was performed by one-step RT-PCR using RNA obtained (RNeasy minikit; Qiagen Hilden, Germany) directly from PBMCs (Table 1) (48).

PBMCs were obtained from blood samples as described above in “Primary cell cultures” and cryopreserved in 90% FBS and 10% dimethyl sulfoxide (DMSO). The samples were thawed, washed in 1⫻ PBS, and split into three aliquots for intracellular staining with mouse anti-flavivirus E protein MAb [4G2; IgG1/IgG2a(␬)], mouse anti-GFP MAb made in-house [isotype control; IgG1(␬)], and mouse anti-NS3 MAb [1722-1B; IgG1(␬)]. Additionally, PBMCs from DV-positive and DV-negative patients were stained using anti-CD3-PE MAb (clone HIT3a), anti-CD14-FITC MAb (clone M5E2), anti-CD8-PerCP MAb (clone SK1), anti-CD19-PE-Cy7 MAb (clone SJ25C1), or anti-CD4-APC MAb (clone RPA-T4) (all antibodies from BD Biosciences) to discriminate different cell populations, as stated above in “Immunophenotyping and DV intracellular labeling.”

Data analysis and statistics.Two-way analysis of variance (ANOVA) followed by the Bonferroni posttest was used for statistical analysis unless otherwise stated in the figure legends.Pvalues of⬍0.05 were considered statistically significant. Pearson correlation analysis was performed between DV infec-tion and apoptosis. The analyses were performed with Prism software (version 5.0c; GraphPad, San Diego, CA, USA). All data from flow cytometry and cell-sorting assays were analyzed in DIVA software version 6.0 (Becton Dickinson) and/or FlowJo version 7.1 (TreeStar, Inc.).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at

https://doi.org/10.1128/JVI

.02181-17

.

SUPPLEMENTAL FILE 1,

PDF file, 0.5 MB.

ACKNOWLEDGMENTS

We thank the Program for Technological Development in Tools for

Health-PDTIS-FIOCRUZ for the use of its facilities (RPT07C, Microscopy Facility, and RPT08L, Flow

Cytometry Facility, at the Carlos Chagas Institute/Fiocruz-PR, Brazil).

W.R.P. (grant number 309239/2015-0), L.R.V.A. (grant number 307408/2016-7), A.B.

(grant number 304875/2014-7), and C.N.D.D.S. (grant number 309432/2015-4) received

CNPq scholarships.

REFERENCES

1. WHO. 2009. Dengue guidelines for diagnosis, treatment, prevention and control. WHO, Geneva, Switzerland.

2. Pang T, Cardosa MJ, Guzman MG. 2007. Of cascades and perfect storms:

[image:17.594.41.372.85.156.2]

the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85:43– 45. https://doi.org/10 .1038/sj.icb.7100008.

TABLE 2Primer pairs used for qPCR assay of DV replication

Gene target Direction Sequence

Fragment

size (bp) Tm(°C)a

NS3 Forward 5=-GACATCTTTCGAAAGAGAAG-3= 160 59

Reverse 5=-AGATACCAAACTCCAGCTAT-3=

18S Forward 5=-CACGGCCGGTACAGTGAAAC-3= 152 59

Reverse 5=-CCCGTCGGCATGTATTAGCT-3=

aT

m, melting temperature.

on November 6, 2019 by guest

http://jvi.asm.org/

(18)

3. Rothman AL, Medin CL, Friberg H, Currier JR. 2014. Immunopathogen-esis versus protection in dengue virus infections. Curr Trop Med Rep 1:13–20.https://doi.org/10.1007/s40475-013-0009-0.

4. Green AM, Beatty PR, Hadjilaou A, Harris E. 2014. Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol 426:1148 –1160.https://doi.org/10.1016/j.jmb.2013.11.023.

5. Kurane I, Ennis FA. 1987. Induction of interferon alpha from human lymphocytes by autologous, dengue virus-infected monocytes. J Exp Med 166:999 –1010.https://doi.org/10.1084/jem.166.4.999.

6. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. 2001. Human dendritic cells are activated by dengue virus infection: enhance-ment by gamma interferon and implications for disease pathogenesis. J Virol 75:3501–3508.https://doi.org/10.1128/JVI.75.8.3501-3508.2001. 7. Lin YW, Wang KJ, Lei HY, Lin YS, Yeh TM, Liu HS, Liu CC, Chen SH. 2002.

Virus replication and cytokine production in dengue virus-infected hu-man B lymphocytes. J Virol 76:12242–12249.https://doi.org/10.1128/JVI .76.23.12242-12249.2002.

8. Espina LM, Valero NJ, Hernandez JM, Mosquera JA. 2003. Increased apoptosis and expression of tumor necrosis factor-alpha caused by infection of cultured human monocytes with dengue virus. Am J Trop Med Hyg 68:48 –53.https://doi.org/10.4269/ajtmh.2003.68.48. 9. Kurane I, Brinton MA, Samson AL, Ennis FA. 1991. Dengue virus-specific,

human CD4⫹CD8⫺cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J Virol 65: 1823–1828.

10. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak A, Kurane I, Rothman AL, Ennis FA. 1999. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemor-rhagic fever. J Infect Dis 180:1429 –1435.https://doi.org/10.1086/315072. 11. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S. 2009. A protective role for dengue virus-specific CD8⫹T cells. J Immunol 182:4865– 4873.https://doi.org/ 10.4049/jimmunol.0801974.

12. Weiskopf D, Bangs DJ, Sidney J, Kolla RV, De Silva AD, de Silva AM, Crotty S, Peters B, Sette A. 2015. Dengue virus infection elicits highly polarized CX3CR1⫹cytotoxic CD4⫹T cells associated with protective immunity. Proc Natl Acad Sci U S A 112:E4256 –E4263.https://doi.org/10.1073/pnas .1505956112.

13. de Matos AM, Carvalho KI, Rosa DS, Villas-Boas LS, da Silva WC, Ro-drigues CL, Oliveira OM, Levi JE, Araujo ES, Pannuti CS, Luna EJ, Kallas EG. 2015. CD8⫹ T lymphocyte expansion, proliferation and activation in dengue fever. PLoS Negl Trop Dis 9:e0003520.https://doi.org/10.1371/ journal.pntd.0003520.

14. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthaworn-chaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hem-orrhagic fever. Nat Med 9:921–927.https://doi.org/10.1038/nm887. 15. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S,

Nisalak A, Lew R, Innis BL, Kurane I, Rothman AL, Ennis FA. 1999. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 179:755–762.https:// doi.org/10.1086/314680.

16. Mathew A, Townsley E, Ennis FA. 2014. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol 9:411– 425.https://doi.org/10.2217/fmb.13.171.

17. Kurane I, Kontny U, Janus J, Ennis FA. 1990. Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infec-tions. Arch Virol 110:91–101.https://doi.org/10.1007/BF01310705. 18. Mentor NA, Kurane I. 1997. Dengue virus infection of human T

lympho-cytes. Acta Virol 41:175–176.

19. Mota J, Rico-Hesse R. 2011. Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS One 6:e20762.https://doi.org/ 10.1371/journal.pone.0020762.

20. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, Jin X. 2008. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononu-clear cells. J Med Virol 80:134 –146.https://doi.org/10.1002/jmv.21051. 21. Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, Rocha C,

Balmaseda A, Harris E. 2008. Phenotyping of peripheral blood mononu-clear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376:429 – 435.https://doi.org/10.1016/j.virol.2008 .03.028.

22. Silveira GF, Meyer F, Delfraro A, Mosimann AL, Coluchi N, Vasquez C, Probst CM, Bafica A, Bordignon J, Dos Santos CN. 2011. Dengue virus type 3 isolated from a fatal case with visceral complications induces enhanced proinflammatory responses and apoptosis of human dendritic cells. J Virol 85:5374 –5383.https://doi.org/10.1128/JVI.01915-10. 23. King AD, Nisalak A, Kalayanrooj S, Myint KS, Pattanapanyasat K,

Nim-mannitya S, Innis BL. 1999. B cells are the principal circulating mononu-clear cells infected by dengue virus. Southeast Asian J Trop Med Public Health 30:718 –728.

24. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, Coppage M, Jin X. 2007. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol 81:13325–13334.https://doi.org/10.1128/JVI.01568-07.

25. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3:866 – 871.https://doi.org/10 .1038/nm0897-866.

26. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. 2002. Heparan sulfate-mediated binding of infec-tious dengue virus type 2 and yellow fever virus. Virology 292:162–168. https://doi.org/10.1006/viro.2001.1232.

27. Dalrymple N, Mackow ER. 2011. Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing pro-teoglycan receptors. J Virol 85:9478 –9485.https://doi.org/10.1128/JVI .05008-11.

28. Voskoboinik I, Whisstock JC, Trapani JA. 2015. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol 15: 388 – 400.https://doi.org/10.1038/nri3839.

29. Limonta D, Torres G, Capo V, Guzman MG. 2008. Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient. Diab Vasc Dis Res 5:213–214.https://doi.org/10.3132/dvdr.2008 .034.

30. Belmokhtar CA, Hillion J, Segal-Bendirdjian E. 2001. Staurosporine in-duces apoptosis through both dependent and caspase-independent mechanisms. Oncogene 20:3354 –3362.https://doi.org/10 .1038/sj.onc.1204436.

31. Correa AR, Berbel AC, Papa MP, Morais AT, Pecanha LM, Arruda LB. 2015. Dengue virus directly stimulates polyclonal B cell activation. PLoS One 10:e0143391.https://doi.org/10.1371/journal.pone.0143391.

32. Hilgard P, Stockert R. 2000. Heparan sulfate proteoglycans initiate den-gue virus infection of hepatocytes. Hepatology 32:1069 –1077.https:// doi.org/10.1053/jhep.2000.18713.

33. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. 1990. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9:1551–1560.

34. Villa NY, Wasserfall CH, Meacham AM, Wise E, Chan W, Wingard JR, McFadden G, Cogle CR. 2015. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood 125:3778 –3788.https://doi.org/10.1182/blood-2014-07-587329. 35. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA.

1991. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest 88:1473–1480.

36. Bade B, Lohrmann J, ten Brinke A, Wolbink AM, Wolbink GJ, ten Berge IJ, Virchow JC, Jr, Luttmann W, Hack CE. 2005. Detection of soluble human granzyme K in vitro and in vivo. Eur J Immunol 35:2940 –2948.https:// doi.org/10.1002/eji.200526249.

37. Marianneau P, Cardona A, Edelman L, Deubel V, Despres P. 1997. Den-gue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. J Virol 71:3244 –3249. 38. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. 1998. Dengue

virus infection of human endothelial cells leads to chemokine produc-tion, complement activaproduc-tion, and apoptosis. J Immunol 161:6338 – 6346. 39. Klomporn P, Panyasrivanit M, Wikan N, Smith DR. 2011. Dengue infection of monocytic cells activates ER stress pathways, but apoptosis is induced through both extrinsic and intrinsic pathways. Virology 409:189 –197. https://doi.org/10.1016/j.virol.2010.10.010.

40. Xu XN, Screaton GR, McMichael AJ. 2001. Virus infections: escape, resis-tance, and counterattack. Immunity 15:867– 870.https://doi.org/10.1016/ S1074-7613(01)00255-2.

41. Gibellini D, Re MC, Ponti C, Vitone F, Bon I, Fabbri G, Di Iasio GM, Zauli G. 2005. HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: a potential

Silveira et al. Journal of Virology

on November 6, 2019 by guest

http://jvi.asm.org/

(19)

molecular mechanism to escape TRAIL cytotoxicity. J Cell Physiol 203: 547–556.https://doi.org/10.1002/jcp.20252.

42. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. 2001. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mecha-nism for protecting the infected host cell. Nature 410:834 – 838.https:// doi.org/10.1038/35071111.

43. Laskus T, Kibler KV, Chmielewski M, Wilkinson J, Adair D, Horban A, Stanczak G, Radkowski M. 2013. Effect of hepatitis C infection on HIV-induced apoptosis. PLoS One 8:e75921.https://doi.org/10.1371/journal .pone.0075921.

44. Despres P, Frenkiel MP, Deubel V. 1993. Differences between cell mem-brane fusion activities of two dengue type-1 isolates reflect modifica-tions of viral structure. Virology 196:209 –219.https://doi.org/10.1006/ viro.1993.1469.

45. Nogueira MB, Stella V, Bordignon J, Batista WC, Borba L, Silva LH, Hoffmann FG, Probst CM, Santos CN. 2008. Evidence for the

co-circulation of dengue virus type 3 genotypes III and V in the Northern region of Brazil during the 2002-2004 epidemics. Mem Inst Oswaldo Cruz 103:483– 488.https://doi.org/10.1590/S0074-02762008000500013. 46. Gould EA, Clegg JCS. 1985. Growth, titration and purification of

togavi-ruses, p 43–78.InMahy BWJ (ed), Virology: a practical approach. IRL Press, Oxford, England.

47. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402– 408.https://doi.org/10.1006/meth.2001.1262. 48. Kuczera D, Bavia L, Mosimann AL, Koishi AC, Mazzarotto GA, Aoki MN,

Mansano AM, Tomeleri EI, Costa Junior WL, Miranda MM, Lo Sarzi M, Pavanelli WR, Conchon-Costa I, Duarte Dos Santos CN, Bordignon J. 2016. Isolation of dengue virus serotype 4 genotype II from a patient with high viral load and a mixed Th1/Th17 inflammatory cytokine profile in South Brazil. Virol J 13:93.https://doi.org/10.1186/s12985-016-0548-9.

on November 6, 2019 by guest

http://jvi.asm.org/

https://doi.org/10.1128/JVI.02181-17 All Rights Reserved. crossm jvi.asm.org on November 6, 2019 by guest S64849.1), KU513442.1), EF629368.1), https://doi.org/10.1038/sj.icb.7100008 https://doi.org/10.1007/s40475-013-0009-0. https://doi.org/10.1016/j.jmb.2013.11.023. https://doi.org/10.1084/jem.166.4.999. https://doi.org/10.1128/JVI.75.8.3501-3508.2001. https://doi.org/10.1128/JVI.76.23.12242-12249.2002 https://doi.org/10.4269/ajtmh.2003.68.48. https://doi.org/10.1086/315072. https://doi.org/10.4049/jimmunol.0801974 https://doi.org/10.1073/pnas.1505956112 https://doi.org/10.1371/journal.pntd.0003520 https://doi.org/10.1038/nm887. https://doi.org/10.1086/314680 https://doi.org/10.2217/fmb.13.171. https://doi.org/10.1007/BF01310705. https://doi.org/10.1371/journal.pone.0020762 https://doi.org/10.1002/jmv.21051. https://doi.org/10.1016/j.virol.2008.03.028 https://doi.org/10.1128/JVI.01915-10. https://doi.org/10.1128/JVI.01568-07. https://doi.org/10.1038/nm0897-866 https://doi.org/10.1006/viro.2001.1232. https://doi.org/10.1128/JVI.05008-11 https://doi.org/10.1038/nri3839. https://doi.org/10.3132/dvdr.2008.034 https://doi.org/10.1038/sj.onc.1204436 https://doi.org/10.1371/journal.pone.0143391. https://doi.org/10.1053/jhep.2000.18713 https://doi.org/10.1182/blood-2014-07-587329. https://doi.org/10.1002/eji.200526249 https://doi.org/10.1016/j.virol.2010.10.010. https://doi.org/10.1016/S1074-7613(01)00255-2 https://doi.org/10.1002/jcp.20252. https://doi.org/10.1038/35071111 https://doi.org/10.1371/journal.pone.0075921 https://doi.org/10.1006/viro.1993.1469 https://doi.org/10.1590/S0074-02762008000500013. https://doi.org/10.1006/meth.2001.1262. https://doi.org/10.1186/s12985-016-0548-9.

Figure

FIG 1 Infection of CD498) at MOIs of 1, 10, and 100, 5 days postinfection. (B and C) Bars represent the average frequencies of mock infection(circles) and DV3 infection (squares) of CD4� and CD8� T lymphocytes with different MOIs of DV3
FIG 3 Detection of CD4� and CD8� T lymphocyte infection using anti-E and anti-NS3 MAbs
FIG 4 Differential susceptibilities of CD4� and CD8� T lymphocytes to DV infection. Bars represent the average frequenciesof CD4� and CD8� T lymphocytes infected by DV1 (A), DV2 (B), DV3 (C), and DV4 (D) at an MOI of 10
FIG 5 Inactivated DV does not infect human T cells. (A) Representative flow cytometry density plotgamma-irradiated DV3 98 (iDV3) and mock infection
+7

References

Related documents